• 1
    Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the “PSA ERA.” Int J Cancer 2001; 92: 8938.
  • 2
    Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 8391.
  • 3
    Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001; 58: 41724.
  • 4
    de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais Da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97: 23744.
  • 5
    Beemsterboer PM, de Koning HJ, Kranse R, Trienekens PH, van der Maas PJ, Schröder FH. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. J Urol 2000; 164: 121620.
  • 6
    Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schröder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 1999; 84: 43741.
  • 7
    Bartelds AIM. Prostaatlijden continue morbiditeits registratie peilstations Nederland 2000. Utrecht: NIVEL, 2001. 1058.
  • 8
    Van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM. Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research. J Epidemiol 1990; 19: 5538.
  • 9
    Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. vol. 7. Lyon: IARC, 1997.
  • 10
    Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction: a registry-based study in southeastern Netherlands, 1971–1995. Eur J Cancer 1998; 34: 7059.
  • 11
    de Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE, et al. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 26873.
  • 12
    Faulkner A, Brookes ST, Donovan J, Selley S, Gillat D, Hamdy F. The use of prostate-specific antigen testing in the detection of localized prostate cancer: current opinion and urological practice in the United Kingdom. Eur J Pub Health 2000; 10: 28995.
  • 13
    IPSTEG. Rationale for randomised trials of prostate cancer screening: the International Prostate Screening Trial Evaluation Group. Eur J Cancer 1999; 35: 26271.
  • 14
    Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer: validation of screening without rectal examination. Urology 2001; 57: 8390.
  • 15
    Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology 2002; 59: 2515.
  • 16
    Páez A, Luján M, Llanes L, Romereo I, de la Cal MA, Miravalles E, et al. PSA-use in a Spanish industrial area. Eur Urol 2002; 41: 1626.